Clinical Trial Update: Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) [Phase 2]

View source ↗

Summary

Phase 2 study assessing pharmacodynamics, efficacy and safety of basiliximab (40 or 80 mg) in combination with cyclosporine microemulsion or everolimus in adult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• Afinitor (everolimus)
• NEORAL (CYCLOSPORINE)
• Simulect (Basiliximab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplantation | Phase 2 | Status: COMPLETED | Results posted: 2014-07-25